Ketoconazole
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Ketoconazole: From Fungal Infections to Acne (Disease)
One-Sentence Summary
Ketoconazole is an imidazole antifungal agent. The TxGNN model predicts it may be effective for Acne (disease), with 1 ongoing clinical trial and 15 related publications (predominantly mechanistic and indirect evidence) currently supporting this direction. Key safety and mechanism-of-action data for this candidate remain unavailable, which limits confidence in the prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Fungal infections (imidazole antifungal); specific approved-indication text not available in this evidence pack |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 99.80% |
| Evidence Level | L3 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ketoconazole is an imidazole antifungal whose efficacy in fungal infections is well established; mechanistically it may also be applicable to acne.
Two plausible mechanistic links connect ketoconazole to acne. First, ketoconazole inhibits steroidogenic enzymes (e.g., CYP17), producing an anti-androgen effect that can reduce sebaceous gland activity — relevant because acne in conditions like PCOS is strongly linked to hyperandrogenism (PMID 19445767, 8090657). Second, ketoconazole directly inhibits the lipase activity of Propionibacterium acnes, reducing the free fatty acids that drive follicular inflammation (PMID 28111792, 20045949).
Additionally, Malassezia (Pityrosporum) species — normal skin flora that ketoconazole's antifungal activity targets — can cause folliculitis that clinically mimics or coexists with acne (PMID 8629828, 8255067, 8593718). This gives a biologically coherent, if indirect, rationale for repurposing. However, because ketoconazole's original indication is fungal infection rather than a dermatologic inflammatory condition, and oral formulations carry known hepatotoxicity concerns, the extrapolation to acne treatment (particularly for any non-topical route) should be treated cautiously pending confirmed MOA and safety data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07237763 | NA | Active, not recruiting | 52 | Randomized comparison of topical ketoconazole 2% cream vs. topical adapalene 2% cream in mild comedonal/papulopustular acne, testing whether ketoconazole is a better-tolerated alternative to topical retinoids. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28111792 | 2017 | Mechanistic study | Microbiology and Immunology | Ketoconazole inhibits P. acnes lipase activity, a proposed direct anti-acne mechanism. |
| 20045949 | 2010 | In vitro study | Biological & Pharmaceutical Bulletin | Azole antifungals, including ketoconazole, show in vitro activity against P. acnes isolated from acne patients. |
| 12566804 | 2003 | Review | Dermatology (Basel) | Overview of systemic acne treatment options and rationale for antimicrobial/anti-inflammatory agents. |
| 8629828 | 1996 | Case series | Archives of Dermatology | Neonatal Malassezia furfur pustulosis, an acne-like eruption linked to fungal infection. |
| 8593718 | 1995 | Case series | Clinical and Experimental Dermatology | Pityrosporum folliculitis frequently misdiagnosed as acne vulgaris; therapeutic trial data included. |
| 8255067 | 1993 | Review | The Keio Journal of Medicine | Pityrosporum ovale implicated in multiple skin conditions including acne-like folliculitis. |
| 19445767 | 2009 | Review | BMJ Clinical Evidence | PCOS review identifying acne as a hyperandrogenism-related manifestation, supporting anti-androgen rationale. |
| 8090657 | 1993 | Review | Polski Tygodnik Lekarski | Hyperandrogenic manifestations including acne improve with anti-androgen therapy in PCOS. |
| 32872149 | 2020 | Review | Pharmaceuticals (Basel) | Review of adapalene, the comparator drug in the active ketoconazole trial. |
New Zealand Market Information
Ketoconazole currently holds no marketing authorization in New Zealand (market status: 未上市／Not Marketed). No product license records are available in the evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: A Blocking data gap (TFDA/package-insert warnings and contraindications) prevents this candidate from entering the S1 safety pre-assessment, and ketoconazole is not currently marketed in New Zealand. Supporting evidence is presently limited to one small, still-active (not yet reported) trial plus indirect mechanistic and case-level literature (Evidence Level L3) — not yet sufficient to proceed.
To proceed, the following is needed:
- TFDA/regulatory package insert (warnings, contraindications) to unblock S1 safety evaluation
- Confirmed mechanism-of-action data from DrugBank or primary literature
- Drug-drug interaction (DDI) data
- Completion and results of NCT07237763
- A larger, controlled trial with completed efficacy/safety outcomes for acne
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.